X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With the termination of its agreement with BMS, Eisai will solely focus on the development & commercialization of MORAb-202 (farletuzumab ecteribulin), is being evaluated for the treatment of NSCLC.
Lead Product(s): Farletuzumab Ecteribulin
Therapeutic Area: Oncology Product Name: MORAb-202
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $3,100.0 million Upfront Cash: $650.0 million
Deal Type: Termination July 01, 2024
Details:
Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
Keytruda (Pembrolizumab) is a PD-1 inhibitor antibody, which is currently being evaluated in combination with lenvatinib for the first-line treatment of patients with advanced nccRCC.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
Leqembi (lecanemab), a humanized IgG1 monoclonal antibody directed against aggregated soluble & insoluble forms of amyloid-beta. It is being evaluated for the treatment of early alzheimer’s disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2024
Details:
Leqembi (lecanemab-irmb) is a humanized IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for Alzheimer’s disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2024
Details:
Fycompa® (perampanel) is a highly selective, non-competitive AMPA glutamate receptor antagonist. It is indicated for the treatment of partial-onset seizures & primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Details:
The net proceeds will be used to evaluate the safety, pharmacokinetic and efficacy profiles of next-generation cPheRS-inhibitor antimalarials, with potentially lower cost of treatment and improved safety profiles.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: The Global Health Innovative Technology
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding May 08, 2024
Details:
The net proceeds will be used for the preclinical development of the macrofilaricide corallopyronin A (CorA) for the treatment of onchocerciasis and lymphatic filariasis.
Lead Product(s): Corallopyronin A
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Global Health Innovative Technology
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Funding May 08, 2024
Details:
The agreement aims to evaluate BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
Lead Product(s): BAN2802
Therapeutic Area: Neurology Product Name: BAN2802
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: BioArctic AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 20, 2024
Details:
Fycompa® (perampanel) is a highly selective, non-competitive AMPA glutamate receptor antagonist. It is indicated for the treatment of partial-onset seizures & primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
